Novacyt, Benchmark Holdings & Ergomed: 3 FTSE-listed biotechnology stocks to buy

August 19, 2021 01:02 PM BST | By Kamalika Ghosh
 Novacyt, Benchmark Holdings & Ergomed: 3 FTSE-listed biotechnology stocks to buy
Image source: Dany_cn, Shutterstock.com

Highlights 

  • Innovations made by the biotech industry made headlines when the Covid-19 vaccines were in progress.
  • Stocks like Novacyt, Benchmark Holdings, and Egromed are some of the stocks that have been making news off late.

The Covid-19 pandemic proved to be an opportunity for the biotechnology industry. Innovations made by the industry remained the headlines when the Covid-19 vaccines were in progress. Apart from the Covid-19 innovations, biotech stocks have been making noise through path-breaking discoveries in the field of medical research.

Here are three biotechnology stocks that have been making a buzz off late:

Novacyt SA (LON:NYCT)

The global specialist in clinical diagnostics announced that its revenue for the first half of 2021 increased 50 per cent to £94.7 million from £63.3 million in the same period a year ago. About £54 million of the total revenue came from a mixture of UK’s growing private testing market as well as overseas sales.

The shares of the company were up 3.77 per cent, trading at GBX 377 on 19 August at 09:09 GMT+1. The shares have a one-year return of 25.83 per cent and have a market capitalisation of £256.66 million. The shares have a price-to-earnings (PE) ratio of 1.94.

Benchmark Holdings Plc (LON:BMK)

The shares of the aquaculture biotechnology company were trading down by 1.40 per cent at GBX 58.10 on 19 August at 09:09 GMT+1. The shares have a one-year return of 41.71 per cent, and its market capitalisation stands at £398.87 million as of 19 August 2021.

The company recently announced that it received Marketing authorisation from the Norwegian Medicines Agency in Norway for the product Ectosan® Vet, which could be a turning point for solving the issues for the salmon industry. Ectosan® Vet would be the milestone in sea lice veterinary treatment, which the Norwegian salmon market has begun over a decade. Sea lice have been detrimental for salmon breeders and have cost then about $1bn globally each year.

Ergomed Plc (LON:ERGO)

The shares of the pharmacovigilance solutions company were up 1.61 per cent, trading at GBX 1,260 with a market capitalisation of £605.53 million as of 12:30 PM on 19 August 2021. The shares have a PE ratio of 48.06.

The company conducts monitoring of drug safety in the development stages and even after the product hits the market. Its clinical research outsourcing wing also offers research management services, including monitoring, reporting, and planning of data from the clinical trials.

CONCLUSION

The biotechnology sector is one of the most sought-after sectors at the moment. With Covid and its long-lasting impact faced by humanity, there is much more focus on research and formulation of new drugs. There would be more innovation and more patent wars that would follow soon.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next